Corium (NSDQ:CORI) announced today that it received FDA approval for its once-daily Azstarys oral capsule for treating ADHD symptoms. Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older, […]
Corium
DaVita taps Javier Rodriguez as CEO | Personnel Moves – April 29, 2019
DaVita Healthcare (NYSE:DVA) said today that its board of directors unanimously elected Javier Rodriguez to succeed Kent Thiry as its new CEO, effective June 1. The Denver-based company said that former CEO Thiry will transition to serve as executive chairman of the board, and that the announcement comes as part of a multi-year succession planning process. […]
Corium touts clinical data for transdermal delivery of Alzheimer’s drug
Corium (NSDQ:CORI) touted data today from a pilot bioequivalence study, comparing its Corplex Donepezil transdermal patch to oral Aricept as delivery method for the most commonly prescribed treatment for Alzheimer’s disease. Data from the pilot study demonstrated that Corium’s transdermal patch met the criteria for bioequivalence to oral Aricept, as measured by primary pharmacokinetic endpoints previously […]
Medicare maintains reimbursement rate for Abiomed heart pump | Medtech Wall Street news for the week of Mar. 24, 2014
Corium poised for $66M IPO for wearable drug-delivery devices
Drug-delivery devices maker Corium could raise up to $66 million through an initial public offering, the company announced in SEC filings today.
Corium plans to offer 5.5 million shares of common stock for $10-$12 apiece, putting its total offering value at between $55-$66 million. At the middle rate of $11 per share, Corium expects its net proceeds to amount to $53.7 million after expenses.
